Azacitidine in patients with WHO-defined AML - Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Pleyer, Lisa ^a   Stauder, Reinhard ^b   Burgstaller, Sonja ^c   Schreder, Martin ^d   Tinchon, Christoph ^e   Pfeilstocker, Michael ^f   Steinkirchner, Susanne ^a   Melchardt, Thomas ^a   Mitrovic, Martina ^b   Girschikofsky, Michael ^g   Lang, Alois ^h   Krippl, Peter ^e   Sliwa, Thamer ⁱ   Egle, Alexander ^a   Linkesch, Werner ^j   Voskova, Daniela ^k   Angermann, Hubert ^l   Greil, Richard ^a  

^a University Hospital Salzburg   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c Hospital Wels Grieskirchen   (Austria)

^d WILHELMINEN HOSPITAL   (Austria)

^e LKH Leoben Eisenerz ^*  (Austria)

^f HANUSCH HOSPITAL   (Austria)

^g ELISABETHINEN HOSPITAL   (Austria)

^h Academic Hospital Feldkirch   (Austria)

ⁱ 5th Medical Department with Oncology und Palliative Medicine   (Austria)

^j MEDICAL UNIVERSITY OF GRAZ   (Austria)

^k KEPLER UNIVERSITY HOSPITAL   (Austria)

^l Unidata Geodesign   (Austria)

more..

Author keywords

AML; Austrian azacitidine registry; Azacitidine; Bone marrow blasts; Overall survival; Prognostic factors

Indexed keywords

AZACITIDINE; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; AUSTRIA; BLAST CELL; BLOOD TOXICITY; BONE MARROW CELL; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOPENIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; INFECTION; INJECTION SITE REACTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PAIN; REGISTER; SEPSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROGNOSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AUSTRIA; AZACITIDINE; COHORT STUDIES; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; REGISTRIES; TREATMENT OUTCOME;

EID: 84876788649     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-32     Document Type: Article

References (42)

1. Prognostic factors in acute myeloid leukaemia. Lowenberg B, Best Pract Res Clin Haematol 2001 14 65 75 10.1053/beha.2000.0116 11355924 (Pubitemid 32380989)
2. The difficult problem of acute myeloid leukemia in the older adult. Stone RM, CA Cancer J Clin 2002 52 363 371 10.3322/canjclin.52.6.363 12469764 (Pubitemid 35446607)
3. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Anderson JE, Kopecky KJ, Willman CL, Head D, O'Donnell MR, Luthardt FW, Blood 2002 100 3869 3876 10.1182/blood-2001-12-0354 12393614 (Pubitemid 35396851)
4. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E, Cancer 2006 106 1090 1098 10.1002/cncr.21723 16435386
5. The outcomes and costs of acute myeloid leukemia among the elderly. Menzin J, Lang K, Earle CC, Kerney D, Mallick R, Arch Intern Med 2002 162 1597 1603 10.1001/archinte.162.14.1597 12123403 (Pubitemid 34773427)
6. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Deschler B, de Witte T, Mertelsmann R, Lubbert M, Haematologica 2006 91 1513 1522 17082009 (Pubitemid 44736118)
7. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Blood 2010 116 4422 4429 10.1182/blood-2010-03-276485 20668231
8. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Cancer 2007 109 1114 1124 10.1002/cncr.22496 17315155 (Pubitemid 46435390)
9. The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. Burnett AK, Russell NH, Culligan D, Cavanagh J, Kell J, Wheatley K, Br J Haematol 2012 158 519 522 10.1111/j.1365-2141.2012.09165.x 22639959
10. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Blood 2008 112 1638 1645 10.1182/blood-2007-11-124602 18565853
11. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. Giles F, Rizzieri D, Karp J, Vey N, Ravandi F, Faderl S, J Clin Oncol 2007 25 25 31 17146105 (Pubitemid 350003047)
12. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Harousseau JL, Martinelli G, Jedrzejczak WW, Brandwein JM, Bordessoule D, Masszi T, Blood 2009 114 1166 1173 10.1182/blood-2009-01-198093 19470696
13. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. Tilly H, Castaigne S, Bordessoule D, Casassus P, Le Prise PY, Tertian G, J Clin Oncol 1990 8 272 279 2299370 (Pubitemid 20056558)
14. A network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderly. Ziogas DC, Voulgarelis M, Zintzaras E, Clin Ther 2011 33 254 279 10.1016/j.clinthera.2011.04.004 21600383
15. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, J Clin Oncol 2006 24 3895 3903 10.1200/JCO.2005.05.4346 16921040 (Pubitemid 46630737)
16. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Lancet Oncol 2009 10 223 232 10.1016/S1470-2045(09) 70003-8 19230772
17. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, J Clin Oncol 2010 28 562 569 10.1200/JCO.2009.23.8329 20026804
18. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Blood 1998 92 2322 2333 9746770 (Pubitemid 28452973)
19. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Blood 2006 108 419 425 10.1182/blood-2005-10-4149 16609072 (Pubitemid 44061337)
20. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, J Clin Oncol 2003 21 4642 4649 10.1200/JCO.2003.04.036 14673054 (Pubitemid 46594039)
21. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Al Ali HK, Jaekel N, Junghanss C, Maschmeyer G, Krahl R, Cross M, Leuk Lymphoma 2012 53 110 117 10.3109/10428194.2011.606382 21767242
22. Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian compassionate program. Maurillo L, Venditti A, Spagnoli A, Gaidano G, Ferrero D, Oliva E, Cancer 2012 118 1014 1022 10.1002/cncr.26354 21761399
23. Treatment of acute myelogenous leukemia with outpatient azacitidine. Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB, Cancer 2006 107 1839 1843 10.1002/cncr.22204 16967444 (Pubitemid 44582953)
24. Treatment of progression of Philadelphia negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies. Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, Blood 2010
25. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. van der Helm LH, Alhan C, Wijermans PW, van Marwijk KM, Schaafsma R, Biemond BJ, Br J Haematol 2011 155 599 606 10.1111/j.1365-2141.2011.08893.x 21981697
26. Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine. Gavillet M, Noetzli J, Blum S, Duchosal MA, Spertini O, Lambert JF, Haematologica 2012 97 1929 1931 10.3324/haematol.2012. 065151 22875616
27. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD, Cohn AL, J Clin Oncol 2009 27 1850 1856 10.1200/JCO.2008.17.1058 19255328
28. The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Burnett AK, Hills RK, Hunter A, Milligan D, Kell J, Wheatley K, Leukemia 2011 25 1122 1127 10.1038/leu.2011.59 21475252
29. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE, Blood 2001 98 1302 1311 10.1182/blood.V98.5.1302 11520775
30. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Quintas-Cardama A, Ravandi F, Liu-Dumlao T, Brandt M, Faderl S, Pierce S, Blood 2012 120 4840 4845 10.1182/blood-2012-06-436055 23071272
31. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. Schiller GJ, O'Brien SM, Pigneux A, Deangelo DJ, Vey N, Kell J, J Clin Oncol 2010 28 815 821 10.1200/JCO.2009.24.2008 20026800
32. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, J Clin Oncol 2012 30 2670 2677 10.1200/JCO.2011.38.9429 22689805
33. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, J Clin Oncol 2002 20 2429 2440 10.1200/JCO.2002.04.117 12011120 (Pubitemid 34525728)
34. Efficacy, tolerability and cost benefit of a 5-Day Azacitidine Regimen. Pierdomenico F, Almeida A, Blood 2011 118 Ref Type: Generic 22279623
35. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellstrom-Lindberg E, Gattermann N, Cancer 2011 117 2697 2702 10.1002/cncr.25774 21656747
36. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients. Ruter B, Wijermans PW, Lubbert M, Cancer 2006 106 1744 1750 10.1002/cncr.21796 16532502
37. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, Blood 2010 116 3724 3734 10.1182/blood-2010-05-282632 20664057
38. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, Blood 2003 102 43 52 10.1182/blood-2002-11-3343 12623843 (Pubitemid 36759634)
39. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as «AML not otherwise specified» (AML-NOS) or «AML with myelodysplasia-related changes» (AML-MRC). Miesner M, Haferlach C, Bacher U, Weiss T, Macijewski K, Kohlmann A, Blood 2010 116 2742 2751 10.1182/blood-2010-04-279794 20581309
40. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Blood 2005 106 2912 2919 10.1182/blood-2005-05-2004 15994282 (Pubitemid 41510773)
41. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Am J Clin Oncol 1982 5 649 655 10.1097/00000421-198212000-00014 7165009 (Pubitemid 13149996)
42. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues Lyon: IARC Press, Swerdlow SH, Harris NL CE, 2008 Ref Type: Generic